3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
7
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Sarcoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colorectal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Risk Syndrome
1
Breast Neoplasms, Male
1
Bone Marrow Failure Disorders
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
1 year
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled